Clevidipine - Revision history

Danbot: Switch SMW query from broadtable to table format for better layout with TOC

2026-03-20T21:57:33Z

Switch SMW query from broadtable to table format for better layout with TOC

← Older revision		Revision as of 21:57, 20 March 2026
Line 64:		Line 64:
	\|?Has Route=Route		\|?Has Route=Route
	\|?Has Population=Population		\|?Has Population=Population
	\|format=~~broadtable~~		\|format=table
	\|headers=plain		\|headers=plain
	\|mainlabel=-		\|mainlabel=-

Danbot: Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

2026-03-20T17:26:45Z

Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

← Older revision		Revision as of 17:26, 20 March 2026
Line 66:		Line 66:
	\|format=broadtable		\|format=broadtable
	\|headers=plain		\|headers=plain
	\|~~link~~=~~subject~~		\|mainlabel=-
	\|sort=Has Indication		\|sort=Has Indication
	\|limit=50		\|limit=50

Danbot: Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)

2026-03-20T16:45:03Z

Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)

@@ Line 53: / Line 53: @@
 ==Comments==
 *$1.67 per mL (25 mg/50mL or 50 mg/100 mL)
 ==See Also==

Elcatracho: /* Serious */

2021-04-08T09:34:44Z

Serious

← Older revision		Revision as of 09:34, 8 April 2021
Line 30:		Line 30:
	==Adverse Reactions==		==Adverse Reactions==
	===Serious===		===Serious===
	*Atrial fibrillation		*[[Atrial fibrillation]]
	*Renal failure		*Renal failure
	*MI (<1%)		*MI (<1%)
	*Intestinal obstruction (<1%)		*Intestinal obstruction (<1%)
	*[[Hypertriglyceridemia]] - similar to [[propofol]], formulated with 20% fat emulsion, risk of developing pancreatitis		*[[Hypertriglyceridemia]] - similar to [[propofol]], formulated with 20% fat emulsion, risk of developing [[pancreatitis]]

	===Common===		===Common===

Elcatracho: /* Mechanism of Action */

2021-04-08T08:48:37Z

Mechanism of Action

← Older revision		Revision as of 08:48, 8 April 2021
Line 49:		Line 49:

	==Mechanism of Action==		==Mechanism of Action==
	Dihydropyridine CCB with arterial vasodilating activity. Inhibits calcium ion influx through L-type calcium channels. Decreases MAP and systemic vascular resistance.		*Dihydropyridine CCB with arterial vasodilating activity. Inhibits calcium ion influx through L-type calcium channels. Decreases MAP and systemic vascular resistance.

	==Comments==		==Comments==

ClaireLewis: /* References */

2019-09-20T17:37:24Z

References

← Older revision		Revision as of 17:37, 20 September 2019
Line 76:		Line 76:
	<references/>		<references/>

	[[Category:Pharmacology]]		[[Category:Pharmacology]] [[Category:Cardiology]]

Fletc151: /* References */

2019-06-13T13:51:06Z

References

@@ Line 61: / Line 61: @@
 ==References==
 <references/>
 [[Category:Pharmacology]]

Mrosen5506: Created page with "==Administration== Type: Calcium channel blockers, anti-hypertensive, dihydropyridine Dosage Forms: 0.5 mg/mL (50 mL, 100 mL) emulsion Routes of Administration: IV Com..."

2018-08-17T17:06:53Z

Created page with "==Administration== *Type: Calcium channel blockers, anti-hypertensive, dihydropyridine *Dosage Forms: 0.5 mg/mL (50 mL, 100 mL) emulsion *Routes of Administration: IV *Com..."

New page

==Administration==
*Type: [[Calcium channel blockers]], anti-hypertensive, dihydropyridine
*Dosage Forms: 0.5 mg/mL (50 mL, 100 mL) emulsion
*Routes of Administration: IV
*Common Trade Names: Cleviprex

==Adult Dosing==
Hypertension
*1-2 mg IV per hour
**Titration: Double dose at 90 second intervals toward blood pressure goal.
***For every 1-2 mg/hour increase should see 2-4 mm Hg reduction

==Special Populations==
===[[Drug pregnancy categories|Pregnancy Rating]]===
*C
===Lactation risk===
*Unknown

===Renal Dosing===
None

===Hepatic Dosing===
None

==Contraindications==
*Allergy to class/drug
*Allergy to soybeans, soy products, eggs, egg products
*Severe aortic stenosis

==Adverse Reactions==
===Serious===
*Atrial fibrillation
*Renal failure
*MI (<1%)
*Intestinal obstruction (<1%)
*[[Hypertriglyceridemia]] - similar to [[propofol]], formulated with 20% fat emulsion, risk of developing pancreatitis

===Common===
*Insomnia
*Nausea
*Fever
*Headache

==Pharmacology==
*Onset: 2-4 minutes
*Half-life: 1 minute
*Metabolism: hydrolysis by esterases in blood
*Excretion: Urine (63-74%); feces (7 to 22%)

==Mechanism of Action==
Dihydropyridine CCB with arterial vasodilating activity. Inhibits calcium ion influx through L-type calcium channels. Decreases MAP and systemic vascular resistance.

==Comments==
*$1.67 per mL (25 mg/50mL or 50 mg/100 mL)

==See Also==
*[[Subarachnoid hemorrhage]]
*[[Hemorrhagic stroke]]
*[[Hypertensive emergency]]
*[[Nicardipine]]

==References==
<references/>

[[Category:Pharmacology]]